A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity.

Trial Profile

A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Muscle spasticity
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jan 2012 Actual patient number is 109 according to ClinicalTrials.gov.
    • 06 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top